Literature DB >> 21183554

Polymorphisms at the regulatory regions of the CASR gene influence stone risk in primary hyperparathyroidism.

Giuseppe Vezzoli1, Alfredo Scillitani, Sabrina Corbetta, Annalisa Terranegra, Elena Dogliotti, Vito Guarnieri, Teresa Arcidiacono, Vera Paloschi, Francesco Rainone, Cristina Eller-Vainicher, Loris Borghi, Antonio Nouvenne, Angela Guerra, Tiziana Meschi, Franca Allegri, Daniele Cusi, Anna Spada, David E C Cole, Geoffrey N Hendy, Donatella Spotti, Laura Soldati.   

Abstract

BACKGROUND AND
OBJECTIVE: Single nucleotide polymorphisms (SNPs) of the calcium-sensing receptor (CASR) gene at the regulatory region were associated with idiopathic calcium nephrolithiasis. To confirm their association with nephrolithiasis, we tested patients with primary hyperparathyroidism (PHPT).
DESIGN: A genotype-phenotype association study.
METHODS: In all, 332 PHPT patients and 453 healthy controls were genotyped for the rs7652589 (G>A) and rs1501899 (G>A) SNPs sited in the noncoding regulatory region of the CASR gene. Allele, haplotype, and diplotype distribution were compared between PHPT patients and controls, and in stone forming and stone-free PHPT patients.
RESULTS: The allele frequency at rs7652589 and rs1501899 SNPs was similar in PHPT patients and controls. The A minor alleles at these two SNPs were more frequent in stone forming (n=157) than in stone-free (n=175) PHPT patients (rs7652589: 36.9 vs 27.1%, P=0.007; rs1501899: 37.1 vs 26.4%, P=0.003). Accordingly, homozygous or heterozygous PHPT patients for the AA haplotype (n=174, AA/AA or AA/GG diplotype) had an increased stone risk (odds ratio 1.83, 95% confidence interval 1.2-2.9, P=0.008). Furthermore, these PHPT patients had higher serum concentrations of ionized calcium and parathyroid hormone (1.50 ± 0.015 mmol/l and 183 ± 12.2 pg/ml) than patients with the GG/GG diplotype (n=145, 1.47 ± 0.011 mmol/l (P=0.04) and 150 ± 11.4 pg/ml (P=0.049)). Using a logistic regression model, the increase in stone risk in PHPT patients was predicted by AA/AA or AA/GG diplotype, the highest tertile of serum ionized calcium values and the lowest tertile of age.
CONCLUSIONS: Polymorphisms located in the regulatory region of the CASR gene may increase susceptibility of the PHPT patients to kidney stone production.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21183554     DOI: 10.1530/EJE-10-0915

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  17 in total

1.  ApaL1 urokinase and Taq1 vitamin D receptor gene polymorphisms in first-stone formers, recurrent stone formers, and controls in a Caucasian population.

Authors:  Serdar Aykan; Murat Tuken; Sezgin Gunes; Yigit Akin; Murat Ozturk; Serkan Seyhan; Emrah Yuruk; Mustafa Zafer Temiz; Ali Faik Yılmaz; Daniel P Nguyen
Journal:  Urolithiasis       Date:  2015-08-15       Impact factor: 3.436

Review 2.  Epidemiology of stone disease across the world.

Authors:  Igor Sorokin; Charalampos Mamoulakis; Katsuhito Miyazawa; Allen Rodgers; Jamsheer Talati; Yair Lotan
Journal:  World J Urol       Date:  2017-02-17       Impact factor: 4.226

Review 3.  International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.

Authors:  Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 4.  Current opinions on nephrolithiasis associated with primary hyperparathyroidism.

Authors:  Xiaoming Cong; Luming Shen; Xiaojian Gu
Journal:  Urolithiasis       Date:  2018-01-19       Impact factor: 3.436

5.  Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calcium nephrolithiasis.

Authors:  Giuseppe Vezzoli; Annalisa Terranegra; Andrea Aloia; Teresa Arcidiacono; Luciano Milanesi; Ettore Mosca; Alessandra Mingione; Donatella Spotti; Daniele Cusi; Jianghui Hou; Geoffrey N Hendy; Laura Soldati; Vera Paloschi; Elena Dogliotti; Caterina Brasacchio; Giacomo Dell'Antonio; Francesco Montorsi; Roberto Bertini; Piera Bellinzoni; Giorgio Guazzoni; Loris Borghi; Angela Guerra; Franca Allegri; Andrea Ticinesi; Tiziana Meschi; Antonio Nouvenne; Antonio Lupo; Antonia Fabris; Giovanni Gambaro; Pasquale Strazzullo; Domenico Rendina; Giampaolo De Filippo; Maria Luisa Brandi; Emanuele Croppi; Luisella Cianferotti; Alberto Trinchieri; Renata Caudarella; Adamasco Cupisti; Franca Anglani; Dorella Del Prete
Journal:  J Clin Endocrinol Metab       Date:  2013-07-17       Impact factor: 5.958

Review 6.  Calcium-sensing receptor: evidence and hypothesis for its role in nephrolithiasis.

Authors:  Giuseppe Vezzoli; Lorenza Macrina; Giulia Magni; Teresa Arcidiacono
Journal:  Urolithiasis       Date:  2018-11-16       Impact factor: 3.436

7.  Risk of nephrolithiasis in primary hyperparathyroidism is associated with two polymorphisms of the calcium-sensing receptor gene.

Authors:  Giuseppe Vezzoli; Alfredo Scillitani; Sabrina Corbetta; Annalisa Terranegra; Elena Dogliotti; Vito Guarnieri; Teresa Arcidiacono; Lorenza Macrina; Alessandra Mingione; Caterina Brasacchio; Cristina Eller-Vainicher; Daniele Cusi; Anna Spada; David E C Cole; Geoffrey N Hendy; Donatella Spotti; Laura Soldati
Journal:  J Nephrol       Date:  2014-05-16       Impact factor: 3.902

Review 8.  Progress in Understanding the Genetics of Calcium-Containing Nephrolithiasis.

Authors:  John A Sayer
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

9.  Clinical impact of hypercalcemia in kidney transplant.

Authors:  Piergiorgio Messa; Cosimo Cafforio; Carlo Alfieri
Journal:  Int J Nephrol       Date:  2011-06-22

10.  Calcium-sensing receptor and aquaporin 2 interplay in hypercalciuria-associated renal concentrating defect in humans. An in vivo and in vitro study.

Authors:  Giuseppe Procino; Lisa Mastrofrancesco; Grazia Tamma; Domenica Rita Lasorsa; Marianna Ranieri; Gilda Stringini; Francesco Emma; Maria Svelto; Giovanna Valenti
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.